Supplementary Materials and Methods, Supplementary Tables 1 and 2, and Supplementary Figures 1 through 8 from Differential Therapeutic Effects of Anti–VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing

<p>PDF - 5513KB, Supplemental Materials & Methods; Supplemental Table 1: Evaluation of MTD chemotherapy in BALB/c mice; Supplemental Table 2: Analysis of changes in the levels of pro-angiogenic cytokines in plasma of mice treated with FOLFOX chemotherapy; Supplemental Figure 1: Growth kinetics of micrometastatic lesions in the lungs of mice implanted with 4T1 or CT26 primary tumors; Supplemental Figure 2: Growth kinetics of advanced macrometastatic lesions in the lungs of mice intravenously injected with 4T1 or CT26 tumor cells; Supplemental Figure 3: The kinetics of CEP levels in the blood of mice treated with FOLFOX or GEM/CDDP; Supplemental Figure 4: Body weight in mice bearing 4T1 or CT-26 tumors following treatment with FOLFOX or GEM/CDDP with or without anti-VEGF-A antibodies; Supplemental Figure 5: The number of MDSCs colonizing 4T1 and CT26 tumors following treatment with FOLFOX or GEM/CDDP with or without anti-VEGF-A antibody; Supplemental Figure 6: Metastasis count in the lungs of mice bearing 4T1 and CT26 experimental or spontaneous metastatic models; Supplemental Figure 7: VEGF-A does not induce invasion of 4T1 and CT26 cells; Supplemental Figure 8: Anti- VEGF blocked FOLFOX-induced liver metastases in LM2-4 tumors.</p>